Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic
Document type Journal Article
Grant support
National Sustainability Program I (NPU I) Nr. LO1503
undefined <span style="color:gray;font-size:10px;">undefined</span>
LO1503
Ministerstvo Školství, Mládeže a Tělovýchovy
Progres Q39
Univerzita Karlova v Praze
CZ.02.1.01/0.0/0.0/17_048/0007280
European Regional Development Fund
NV19-08-00250
Ministerstvo Zdravotnictví Ceské Republiky
Nº856620
Horizon 2020
PubMed
32230921
PubMed Central
PMC7225945
DOI
10.3390/cancers12040808
PII: cancers12040808
Knihovny.cz E-resources
- Keywords
- Memorial Sloan–Kettering Cancer Center risk, first line, outcome, renal cell carcinoma, sunitinib,
- Publication type
- Journal Article MeSH
BACKGROUND: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. METHODS: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. RESULTS: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). CONCLUSIONS: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
See more in PubMed
Znaor A., Lortet-Tieulent J., Laversanne M., Jemal A., Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 2015;67:519. doi: 10.1016/j.eururo.2014.10.002. PubMed DOI
Srigley J.R., Delahunt B., Eble J.N., Egevad L., Epstein J.I., Grignon D., Hes O., Moch H., Montironi R., Tickoo S.K., et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am. J. Surg. Pathol. 2013;37:1469–1489. doi: 10.1097/PAS.0b013e318299f2d1. PubMed DOI
Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002;20:289–296. doi: 10.1200/JCO.20.1.289. PubMed DOI
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009;27:3584–3590. doi: 10.1200/JCO.2008.20.1293. PubMed DOI PMC
Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010;28:1061–1068. doi: 10.1200/JCO.2009.23.9764. PubMed DOI
Buchler T., Klapka R., Melichar B., Brabec P., Dusek L., Vyzula R., Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma – data from the Czech registry. Ann. Oncol. 2012;23:395–401. doi: 10.1093/annonc/mdr065. PubMed DOI
Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000;3:205–216. doi: 10.1093/jnci/92.3.205. PubMed DOI
Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999;17:2530–2540. doi: 10.1200/JCO.1999.17.8.2530. PubMed DOI
Mekhail T.M., Abou-Jawde R.M., Boumerhi G., Malhi S., Wood L., Elson P., Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 2005;23:832–841. doi: 10.1200/JCO.2005.05.179. PubMed DOI
Heng D.Y., Xie W., Regan M.M., Harshman L.C., Bjarnason G.A., Vaishampayan U.N., Mackenzie M., Wood L., Donskov F., Tan M.H., et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141–148. doi: 10.1016/S1470-2045(12)70559-4. PubMed DOI PMC
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007;356:115–124. doi: 10.1056/NEJMoa065044. PubMed DOI
Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J., Nathan P., Staehler M., de Souza P., Merchan J.R., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 2013;369:722–731. doi: 10.1056/NEJMoa1303989. PubMed DOI
Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111. doi: 10.1016/S0140-6736(07)61904-7. PubMed DOI
Hutson T.E., Lesovoy V., Al-Shukri S., Stus V.P., Lipatov O.N., Bair A.H., Rosbrook B., Chen C., Kim S., Vogelzang N.J. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287–1294. doi: 10.1016/S1470-2045(13)70465-0. PubMed DOI
Choueiri T.K., Halabi S., Sanford B.L., Hahn O., Michaelson M.D., Walsh M.K., Feldman D.R., Olencki T., Picus J., Small E.J., et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J. Clin. Oncol. 2017;35:591–597. doi: 10.1200/JCO.2016.70.7398. PubMed DOI PMC
Motzer R.J., Tannir N.M., McDermott D.F., Arén Frontera O., Melichar B., Choueiri T.K., Plimack E.R., Barthélémy P., Porta C., George S., et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2018;378:1277–1290. doi: 10.1056/NEJMoa1712126. PubMed DOI PMC
Rini B.I., Plimack E.R., Stus V., Gafanov R., Hawkins R., Nosov D., Pouliot F., Alekseev B., Soulières D., Melichar B., et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019;380:1116–1127. doi: 10.1056/NEJMoa1816714. PubMed DOI
Rini B.I., Powles T., Atkins M.B., Escudier B., McDermott D.F., Suarez C., Bracarda S., Stadler W.M., Donskov F., Lee J.L., et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393:2404–2415. doi: 10.1016/S0140-6736(19)30723-8. PubMed DOI
Motzer R.J., Penkov K., Haanen J., Rini B., Albiges L., Campbell M.T., Venugopal B., Kollmannsberger C., Negrier S., Uemura M., et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2019;380:1103–1115. doi: 10.1056/NEJMoa1816047. PubMed DOI PMC
Rini B.I., Hutson T.E., Figlin R.A., Lechuga M.J., Valota O., Serfass L., Rosbrook B., Motzer R.J. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin. Genitourin Cancer. 2018;16:298–304. doi: 10.1016/j.clgc.2018.04.005. PubMed DOI PMC
Kubackova K., Melichar B., Bortlicek Z., Pavlik T., Poprach A., Svoboda M., Lakomy R., Vyzula R., Kiss I., Dusek L., et al. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. Target. Oncol. 2015;10:557–563. doi: 10.1007/s11523-015-0366-9. PubMed DOI
Kwon W.A., Cho I.C., Yu A., Nam B.H., Joung J.Y., Seo H.K., Lee K.H., Chung J. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. Ann. Surg. Oncol. 2013;20:4397–4404. doi: 10.1245/s10434-013-3290-1. PubMed DOI
Bamias A., Karadimou A., Lampaki S., Lainakis G., Malettou L., Timotheadou E., Papazisis K., Andreadis C., Kontovinis L., Anastasiou I., et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer. 2010;10:45. doi: 10.1186/1471-2407-10-45. PubMed DOI PMC
Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., Lee S.H., Haanen J., Castellano D., Vrdoljak E., et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br. J. Cancer. 2015;113:9–12. doi: 10.1038/bjc.2015.196. PubMed DOI PMC
Motzer R.J., Nosov D., Eisen T., Bondarenko I., Lesovoy V., Lipatov O., Tomczak P., Lyulko O., Alyasova A., Harza M., et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J. Clin. Oncol. 2013;31:3791–3799. doi: 10.1200/JCO.2012.47.4940. PubMed DOI PMC
Eichelberg C., Vervenne W.L., De Santis M., Fischer von Weikersthal L., Goebell P.J., Lerchenmüller C., Zimmermann U., Bos M.M., Freier W., Schirrmacher-Memmel S., et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenibsunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur. Urol. 2015;68:837–847. doi: 10.1016/j.eururo.2015.04.017. PubMed DOI
Sella A., Michaelson M.D., Matczak E., Simantov R., Lin X., Figlin R.A. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clin Genitourin Cancer. 2017;15:291–299. doi: 10.1016/j.clgc.2016.08.013. PubMed DOI
Tamada S., Iguchi T., Yasuda S., Kato M., Yamasaki T., Nakatani T. The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria. Oncotarget. 2018;9:27752–27759. doi: 10.18632/oncotarget.25554. PubMed DOI PMC
Miyazaki A., Miyake H., Harada K.I., Inoue T.A., Fujisawa M. Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. Mol. Clin. Oncol. 2015;3:601–606. doi: 10.3892/mco.2015.487. PubMed DOI PMC
Melichar B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clin. Chem. Lab. Med. 2013;51:99–112. doi: 10.1515/cclm-2012-0496. PubMed DOI
Ravaud A., Barrios C.H., Alekseev B., Tay M.H., Agarwala S.S., Yalcin S., Lin C.C., Roman L., Shkolnik M., Anak O., et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 2015;26:1378–1384. doi: 10.1093/annonc/mdv170. PubMed DOI
Non-coding transcriptome profiles in clear-cell renal cell carcinoma
